ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Hyun Jung Lee, Jong Eun Yeon, Eun Jung Ko, Eileen L Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seoung Hee Kang, Yang Jae Yoo, Jihye Je, Beom Jae Lee, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim and Kwan Soo Byun |
Funding Agency and Grant Number |
|
Corresponding Author |
Jong Eun Yeon, MD, PhD, Department of Internal Medicine, Korea University College of Medicine, 97 Guro-Dong Gil, Guro-Dong, Guro-Ku, Seoul 152-703,
South Korea. jeyyeon@hotmail.com
|
Key Words |
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Inflammasome; Nucleotide-binding and oligomerization domain-like receptor; Peroxisome proliferator-activated receptors delta |
Core Tip |
Until now, the underlying mechanisms of disease progression and therapeutic targets were uncertain in nonalcoholic fatty liver disease (NAFLD). Our study were to evaluate the inflammasome activation and the effect of peroxisome proliferator-activated receptors (PPAR)-δ agonist treatment in NAFLD models. In our NAFLD models, mRNA of several NOD-like receptor family members, caspase-1 and interleukin-1β were markedly increased. All of those effects were reduced by PPAR-δ agonist treatment. It also ame-liorated the steatosis and inhibited overexpression of pro-inflammatory cytokines. In conclusion, PPAR-δ agonist reduces fatty acid-induced inflammation and steatosis by suppressing inflammasome activation.
|
Publish Date |
2015-12-06 13:18 |
Citation |
Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(45): 12787-12799 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i45/12787.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i45.12787 |